NCT02760342 is a Phase 1 clinical trial of peficitinib in Healthy Subjects, sponsored by Astellas Pharma Inc.

Who is sponsoring NCT02760342?

NCT02760342 is sponsored by Astellas Pharma Inc.

What drugs are being tested in NCT02760342?

Interventions in NCT02760342: peficitinib, Metformin.

What condition does NCT02760342 study?

NCT02760342 studies Healthy Subjects.

Is NCT02760342 still recruiting?

NCT02760342 is currently completed. Last updated 16 October 2024.

Last reviewed 2024-10-16 · How we verify

NCT02760342

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Metformin

Completed Phase 1 Last updated 16 October 2024

What this trial tests

Phase 1 trial testing peficitinib in Healthy Subjects in 24 participants. Completed in 26 June 2016.

Timeline

15 May 2016

Primary endpoint
26 June 2016

26 June 2016

Quick facts

Lead sponsor	Astellas Pharma Inc
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	24
Start date	15 May 2016
Primary completion	26 June 2016
Estimated completion	26 June 2016
Sites	1 location across Japan

Drugs / interventions tested

peficitinib — full drug profile →
Metformin (metformin) — full drug profile →

Conditions studied

Healthy Subjects — all drugs for Healthy Subjects →

Sponsor

Astellas Pharma Inc — full company profile →

Who can join

Adults 20 to 44, male only, with Healthy Subjects. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to evaluate the pharmacokinetic interactions between ASP015K and metformin in healthy non-elderly male subjects.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

A drug-drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers.
Shibata M, Toyoshima J, Kaneko Y, Oda K, et al · · 2020 · cited 14× · PMID 32472157 · DOI 10.1007/s00228-020-02876-2
Population pharmacokinetic analysis of peficitinib in patients with rheumatoid arthritis.
Toyoshima J, Shibata M, Kaibara A, Kaneko Y, et al · · 2021 · cited 10× · PMID 33068028 · DOI 10.1111/bcp.14605

Verify or expand the search:

Other trials of peficitinib

Trials testing the same drug.

NCT04143477 — A Study to Evaluate the Pharmacokinetics and Safety of ASP015K in Healthy Chinese Subjects · Phase 1 · completed
NCT02531191 — Bioequivalence Evaluation of a New and Current Tablet of ASP015K · Phase 1 · completed
NCT01711814 — A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rh · Phase 2 · completed
NCT01554696 — A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had · Phase 2 · completed
NCT01565655 — A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis · Phase 2 · completed

Other recruiting trials for Healthy Subjects

Currently open trials in the same condition.

NCT07222020 — Phase 1 Study of Intravaginal KB15A · Phase 1 · recruiting
NCT07350538 — The Critical Link Between Gut Microbiome Dysfunction, Cravings and Relapse: RECLAIM-GUT TRIAL · NA · active not recruiting
NCT07304791 — This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and P · Phase 1 · recruiting
NCT07059858 — Bladder and Bowel Functions, Participation and Quality of Life in Children With Intellectual Disabilities · recruiting
NCT07331389 — A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin · Phase 1 · recruiting

Other Astellas Pharma Inc trials

Trials by the same sponsor.

NCT07318714 — A Study of ASP2246 for People Who Have Movement Problems Caused by Brain Injury After a Stroke · Phase 1, PHASE2 · recruiting
NCT07094204 — A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors · Phase 1 · recruiting
NCT06970665 — A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Ma · Phase 4 · recruiting
NCT06364696 — A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors · Phase 1 · active not recruiting
NCT06206421 — A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02760342 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Astellas Pharma Inc
Last refreshed: 16 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02760342.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing